Bacille-Calmette-Guerin Non-Responders: How to Manage
Bacille-Calmette-Guerin Non-Responders: How to Manage
Docetaxel is a taxane and used as a chemotherapy agent in metastatic prostate and breast cancer. McKiernan et al. have previously demonstrated that it can be safely used in intravesical therapy and showed a 56% response rate in patients with BCG refractory disease. More recently Barlow et al. presented results from a single center analysis of 54 patients who had failed at least one course of prior BCG with or without interferon. After the first induction cycle 59% of patients had a CR to docetaxel. One- and three-year recurrence-free survival rates were 40% and 25% respectively. The analysis did not reveal a benefit for a monthly maintenance schedule for up to 9 months after the first three months control.
Docetaxel
Docetaxel is a taxane and used as a chemotherapy agent in metastatic prostate and breast cancer. McKiernan et al. have previously demonstrated that it can be safely used in intravesical therapy and showed a 56% response rate in patients with BCG refractory disease. More recently Barlow et al. presented results from a single center analysis of 54 patients who had failed at least one course of prior BCG with or without interferon. After the first induction cycle 59% of patients had a CR to docetaxel. One- and three-year recurrence-free survival rates were 40% and 25% respectively. The analysis did not reveal a benefit for a monthly maintenance schedule for up to 9 months after the first three months control.
Source...